Literature DB >> 33928568

Stick-Based Methods for Aptamer-Mediated siRNA Targeted Delivery.

Silvia Catuogno1, Carla Lucia Esposito2, Paloma H Giangrande3.   

Abstract

Despite the therapeutic utility of small interfering RNA (siRNA) molecules, the development of a safe and reliable method to selectively target diseased organs and tissues is still a critical need for their translation to the clinic. Here we describe how nucleic acid-based aptamers against cell surface epitopes may be used to address this issue. We discuss the most recent examples and advances in the field of aptamer siRNA delivery and provide a fast and simple protocol for the design and generation of aptamer-siRNA chimeras. The described approach is based on the annealing of the targeting aptamer, and the antisense strand through "stick" complementary sequences elongated at their 3' end, and the subsequent paring with the sense strand. Such a protocol allows a modular non-covalent generation of the constructs and permits an efficient delivery of the siRNA moiety into aptamer target cells.

Keywords:  Aptamers; Non-covalent constructs; Targeted delivery; Targeted therapy; siRNAs

Year:  2021        PMID: 33928568     DOI: 10.1007/978-1-0716-1298-9_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

Review 1.  Aptamers: current challenges and future prospects.

Authors:  Guido Tomás Rozenblum; Vanina Gisela Lopez; Alfredo Daniel Vitullo; Martín Radrizzani
Journal:  Expert Opin Drug Discov       Date:  2015-12-18       Impact factor: 6.098

2.  An RNA motif that binds ATP.

Authors:  M Sassanfar; J W Szostak
Journal:  Nature       Date:  1993-08-05       Impact factor: 49.962

3.  High-resolution molecular discrimination by RNA.

Authors:  R D Jenison; S C Gill; A Pardi; B Polisky
Journal:  Science       Date:  1994-03-11       Impact factor: 47.728

4.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

5.  Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity.

Authors:  Anugraha Rajagopalan; Alexey Berezhnoy; Brett Schrand; Yvonne Puplampu-Dove; Eli Gilboa
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

6.  Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells.

Authors:  Adi Gilboa-Geffen; Peter Hamar; Minh T N Le; Lee Adam Wheeler; Radiana Trifonova; Fabio Petrocca; Anders Wittrup; Judy Lieberman
Journal:  Mol Cancer Ther       Date:  2015-08-11       Impact factor: 6.261

7.  RNA aptamers that bind L-arginine with sub-micromolar dissociation constants and high enantioselectivity.

Authors:  A Geiger; P Burgstaller; H von der Eltz; A Roeder; M Famulok
Journal:  Nucleic Acids Res       Date:  1996-03-15       Impact factor: 16.971

8.  EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.

Authors:  Nithya Subramanian; Jagat R Kanwar; Rupinder K Kanwar; JagadeeshBabu Sreemanthula; Jyotirmay Biswas; Vikas Khetan; Subramanian Krishnakumar
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

9.  EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.

Authors:  Tao Wang; Michael P Gantier; Dongxi Xiang; Andrew G Bean; Matthew Bruce; Shu-Feng Zhou; Mustafa Khasraw; Alister Ward; Li Wang; Ming Q Wei; Hadi AlShamaileh; Lijue Chen; Xiaodong She; Jia Lin; Lingxue Kong; Sarah Shigdar; Wei Duan
Journal:  Theranostics       Date:  2015-10-20       Impact factor: 11.556

Review 10.  Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Garima Sharma; C George Priya Doss; Sang-Soo Lee
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-12       Impact factor: 8.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.